Eli Lilly LLY Business Segments
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Revenue by Product | |||||
| Jardiance | $3.43B+2.7% | $3.34B+21.7% | $2.75B+32.9% | $2.07B+38.6% | |
| Mounjaro | $22.97B+99.0% | $11.54B+124% | $5.16B+970% | $482.6M— | |
| Neuroscience | $1.39B-5.6% | $1.47B-48.8% | $2.88B+86.2% | $1.55B-18.6% | |
| Other cardiometabolic health | $4.01B-10.2% | $4.46B+0.2% | $4.45B+796% | $496.9M— | |
| Other immunology | $1.68B+48.6% | $1.13B+9.2% | $1.04B+3,134% | $32.1M-2.4% | |
| Other oncology | $3.65B+6.0% | $3.45B+23.3% | $2.79B+107% | $1.35B+309% | |
| Taltz | $3.56B+9.3% | $3.26B+18.1% | $2.76B+11.2% | $2.48B+12.2% | |
| Trulicity | $4.28B-18.6% | $5.25B-26.3% | $7.13B-4.1% | $7.44B+15.0% | |
| Verzenio | $5.72B+7.8% | $5.31B+37.4% | $3.86B+55.5% | $2.48B+84.0% | |
| Zepbound | $13.54B+175% | $4.93B+2,699% | $176M— | $0— | |
| Potential achievements by Product | |||||
| Ebglyss | $4.95B-1.0% | $5B— | —— | —— | |
| R&D by Product | |||||
| Early-stage | $4.88B+24.6% | $3.92B+26.6% | $3.09B+28.5% | $2.41B— | |
| Late-stage | $8.46B+19.5% | $7.07B+13.7% | $6.22B+30.0% | $4.78B— | |
| Revenue by Geography | |||||
| China | $1.95B+17.5% | $1.66B+7.8% | $1.54B+6.0% | $1.45B-12.6% | |
| Europe | $11.56B+67.0% | $6.92B+12.1% | $6.18B+43.6% | $4.3B-10.0% | |
| Japan | $2.13B+17.5% | $1.82B+8.5% | $1.67B-4.3% | $1.75B-26.2% | |
| Outside U.S. | $21.7B+47.9% | $14.67B+18.9% | $12.33B+19.1% | $10.35B-10.0% | |
| Rest of world | $6.06B+41.8% | $4.27B+45.0% | $2.95B+3.3% | $2.85B— | |
| U.S. | $43.48B+43.1% | $30.38B+39.4% | $21.79B+19.8% | $18.19B+8.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Eli Lilly break its business down?
- Eli Lilly (LLY) reports revenue by product across 10 parts — Jardiance, Mounjaro, Neuroscience, Other cardiometabolic health and Other immunology. Each is extracted from the segment footnotes and tracked over time.
- Where does Eli Lilly's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Eli Lilly's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
